Entrada Therapeutics (NASDAQ:TRDA) Major Shareholder Bioventures 2018 L.P. Mpm Sells 25,131 Shares

Entrada Therapeutics, Inc. (NASDAQ:TRDA) major shareholder Bioventures 2018 L.P. Mpm sold 25,131 shares of the company’s stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $7.19, for a total value of $180,691.89. Following the completion of the transaction, the insider directly owned 4,177,215 shares of the company’s stock, valued at approximately $30,034,175.85. The trade was a 0.60% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Large shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

Bioventures 2018 L.P. Mpm also recently made the following trade(s):

• On Thursday, September 3rd, Bioventures 2018 L.P. Mpm sold 32,263 shares of Entrada Therapeutics stock. The shares were sold at an average price of $7.17, for a total value of $231,325.71.
• On Tuesday, September 1st, Bioventures 2018 L.P. Mpm sold 29,088 shares of Entrada Therapeutics stock. The stock was sold at an average price of $7.06, for a total value of $205,361.28.
• On Monday, August 31st, Bioventures 2018 L.P. Mpm sold 44,259 shares of Entrada Therapeutics stock. The shares were sold at an average price of $6.99, for a total transaction of $309,370.41.
• On Friday, August 28th, Bioventures 2018 L.P. Mpm sold 3,733 shares of Entrada Therapeutics stock. The stock was sold at an average price of $7.01, for a total transaction of $26,168.33.
• On Thursday, August 27th, Bioventures 2018 L.P. Mpm sold 38,922 shares of Entrada Therapeutics stock. The stock was sold at an average price of $7.20, for a total transaction of $280,238.40.

Entrada Therapeutics Price Performance

TRDA opened at $7.17 on Friday. Entrada Therapeutics, Inc. has a fifty-two week low of $5.02 and a fifty-two week high of $16.45. The company’s 50 day moving average price is $7.08 and its two-hundred day moving average price is $9.20. The firm has a market capitalization of $279.20 million, a price-to-earnings ratio of -1.81 and a beta of -0.25.

Entrada Therapeutics (NASDAQ:TRDA) last released its quarterly earnings results on Wednesday, August 5th. The company reported ($1.01) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.97) by ($0.04). The business had revenue of $0.90 million for the quarter, compared to the consensus estimate of $2.32 million. Entrada Therapeutics had a negative net margin of 3,537.73% and a negative return on equity of 57.61%. As a group, equities research analysts predict that Entrada Therapeutics, Inc. will post -4.03 EPS for the current year.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on TRDA. Guggenheim lowered their target price on Entrada Therapeutics from $20.00 to $17.00 and set a “buy” rating for the company in a research report on Monday, June 8th. Weiss Ratings upgraded Entrada Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday. HC Wainwright cut Entrada Therapeutics from a “buy” rating to a “neutral” rating in a research note on Friday, May 8th. Finally, Roth Capital restated a “buy” rating and set a $11.00 price objective on shares of Entrada Therapeutics in a research report on Wednesday, August 12th. Four investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Entrada Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $17.75.

Institutional Investors Weigh In On Entrada Therapeutics

A number of institutional investors have recently modified their holdings of TRDA. State of Wyoming bought a new stake in shares of Entrada Therapeutics in the 2nd quarter valued at $37,000. Russell Investments Group Ltd. raised its stake in Entrada Therapeutics by 72.7% during the third quarter. Russell Investments Group Ltd. now owns 8,808 shares of the company’s stock worth $51,000 after buying an additional 3,707 shares during the last quarter. Occudo Quantitative Strategies LP bought a new position in Entrada Therapeutics during the second quarter worth $68,000. Jain Global LLC acquired a new position in Entrada Therapeutics in the third quarter valued at $69,000. Finally, IHT Wealth Management LLC acquired a new position in Entrada Therapeutics in the second quarter valued at $72,000. 86.39% of the stock is owned by institutional investors.

Entrada Therapeutics Company Profile

Entrada Therapeutics (NASDAQ: TRDA) is a clinical-stage biotechnology company focused on enabling the development of protein-based therapeutics that can cross cell membranes and engage intracellular targets. Using its proprietary cell-penetrating miniature protein (CPMP) platform and intracellular targeting of proteins (iTOP) delivery technology, Entrada aims to expand the range of diseases addressable by large-molecule drugs.

The company’s pipeline includes programs in rare and serious diseases where conventional biologics have limited intracellular activity.